Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
    All Public Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • Eleven Minutes
    All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Vaccine Policy in Colorado
  • Family Separation
  • Shakeup at U.S. Preventive Services Task Force
  • Ebola
  • ACA Enrollment

WHAT'S NEW

  • Vaccine Policy in Colorado
  • Family Separation
  • Shakeup at U.S. Preventive Services Task Force
  • Ebola
  • ACA Enrollment

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Wednesday, May 10 2023

Full Issue

FDA Scientists Have 2 Major Qualms About OTC Birth Control Pills

Advisers met Tuesday to discuss the pros and cons of selling Opill, a progestin-only birth control pill, without a prescription. Their concerns focused on efficacy from obesity and whether users will follow the instructions. The panel will take a nonbinding vote today.

The New York Times: F.D.A. Advisers Weigh Allowing First U.S. Over-The-Counter Birth Control Pill 

It was like a tale of two birth control pills. At a hearing Tuesday to consider whether the Food and Drug Administration should authorize the country’s first over-the-counter birth control pill, a panel of independent medical experts advising the agency was left to reckon with two contradictory analyses of the medication called Opill. (Belluck, 5/9)

CNN: As FDA Advisers Consider OTC Birth-Control Pill, Agency Scientists Worry It Won’t Work Due To Women’s Weight And Likelihood Of Following Label

The FDA scientists say they have two main concerns about Opill, a “mini pill” that uses only the hormone progestin. One has to do with obesity. The FDA approved Opill as a prescription drug in 1973, and “the prevalence of obesity in adults in the United States has changed dramatically since the original clinical studies were conducted over 50 years ago,” the scientists wrote in the document, citing a 13% obesity rate in 1960 compared with a 42% obesity rate now. (Cohen and Sealy, 5/9)

Abortion updates from North Carolina, Virginia, South Carolina, and Ohio —

VPM: North Carolina Abortion Bill Could Heighten Stakes In Virginia 

A North Carolina bill that would ban most abortions past 12 weeks of pregnancy could have major consequences for Virginia providers, patients and legislative races if it becomes law, according to groups involved in the debate. North Carolina’s Democratic governor, Roy Cooper, has vowed to veto the bill, which would also place major restrictions on abortion providers. Republicans hold enough seats in the state’s Legislature to overrule a veto, but Cooper urged several members of the Republican super-majority to buck their party. (Paviour, 5/8)

AP: South Carolina Republicans Advance New Abortion Restrictions 

South Carolina Republicans are pushing new abortion restrictions in a late attempt to curtail access after a near-total ban failed last month. A Senate bill that would ban abortion except in the earliest weeks of pregnancy is moving quickly through the South Carolina House in the first sign that Republican leaders may be close to restoring limits passed in 2021 but overturned by the state Supreme Court. The effort cleared two hurdles Tuesday. (Pollard, 5/10)

Reuters: Ohio Abortion Rights Fight Highlights Republican Electoral Vulnerabilities 

Republican vulnerabilities on abortion policy are on display in Ohio, with the party playing defense against a surge in abortion rights activism that could help President Joe Biden and his Democratic Party in next year's elections. Facing a Wednesday deadline, Republicans have spent weeks preparing a measure that could make it more difficult for voters to approve a state constitutional amendment protecting abortion rights that Democrats and activists are working to get on the ballot in November. (Lange, Borter and Ax, 5/10)

Also —

Military.com: Mifepristone Probably Won't Work As A Treatment For Combat PTSD, New Study Finds

More than a decade ago, the now controversial medication mifepristone showed promise for alleviating symptoms of service-related post-traumatic stress disorder in men. A new study published Tuesday, however, counters previous research, determining that, in most cases, the drug used in medication abortions currently facing judicial review in the U.S. court system is no more effective for treating military PTSD than a placebo. (Kime, 5/9)

NPR: Maternity Home Provides A Place For Women Who Decide Not To Have An Abortion 

Called the Nesting Place, it's part of a Christian organization in Nampa, Idaho, that tries to dissuade people from abortion and persuade them to take up parenthood. Women can live in the home for free while they carry pregnancies. After their babies are born, they can stay for six months longer. (5/9)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, May 21
  • Wednesday, May 20
  • Tuesday, May 19
  • Monday, May 18
  • Friday, May 15
  • Thursday, May 14
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF